(Q33904308)

29 July 2017

1 reference

title

Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease (English)

1 reference

29 July 2017

0 references

Bell SJ

1

1 reference

29 July 2017

Kamm MA

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

Alimentary Pharmacology & Therapeutics

29 July 2017

published in

1 reference

29 July 2017

volume

14

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

501-514

1 reference

Humanized antibodies for therapy

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Adult T-cell leukemia with HTLV-I-associated myelopathy after complete remission of acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Anal complications in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

The relationship between infliximab treatment and lymphoma in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Lower gastrointestinal malignancy in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

A controlled double blind study of azathioprine in the management of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Controlled trial of azathioprine in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Risk of cancer in renal-transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Methotrexate in refractory Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Methotrexate for inflammatory bowel disease: pharmacology and preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Cyclosporin A treatment in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Efficacy of cyclosporine in treatment of fistula of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

Low-Dose Cyclosporine for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00777.X

10.1046/J.1365-2036.2000.00777.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference